Forming a multidisciplinary clinic for patients with HCC resulted in improved survival, likely due to more streamlined care and earlier diagnosis, found research presented at SSO 2013.
Major challenges exist for hospitals with respect to publicly reported cancer metrics, according to research presented at SSO 2013.
Adding alvimopan to an established fast-track enhanced recovery protocol significantly decreased length of stay and overall treatment cost in patients undergoing elective bowel resection for cancer, found research presented at SSO 2013.
Elevated Preoperative C-Reaction Protein Associated with Worse Survival in Patients Undergoing Palliative Procedures
Patients with advanced cancer who are less likely to benefit from palliative procedures often have elevated preoperative C-reaction protein, according to research presented at SSO 2013.
Similar Disease-Specific Survival Rates Reported for Pre- and Post-Surgical Ipilimumab for Stage 4 Melanoma
Disease-specific survival appears not to be significantly different between patients with stage 4 melanoma who are administered ipilimumab before surgical resection and those who receive ipilimumab therapy after surgery, according to research presented at SSO 2013.
Despite significant toxicity, the FOLFIRINOX chemotherapy regimen is associated with clinical responses among patients with locally advanced pancreatic ductal adenocarcinoma, according to research presented at SSO 2013.
Adding sunitinib to tamoxifen antiestrogen therapy might prove to be a promising treatment strategy for estrogen receptor-positive breast cancer, according to research presented at SSO 2013.
Intraperitoneal and Intravenous Paclitaxel + Combination Chemotherapy Effective in Peritoneal Metastasis
Combination chemotherapy with S-1—oral tegafur, gimeracil, and oteracil potassium—and IV and intraperitoneal paclitaxel was well-tolerated and very effective in patients with gastric cancer and peritoneal metastasis, according to research presented at SSO 2013.
Sentinel lymph node biopsy provides prognostic information and is independently associated with improved survival in patients with Merkel cell carcinoma, according to research presented at SSO 2013.
Genetic Recurrence Score Predicts Locoregional Risk in Node-Positive, ER-Positive Breast Cancer After Adjuvant Chemotherapy and Tamoxifen
A 21-gene recurrence risk score also predicts locoregional recurrence among patients with node-positive ER-positive breast cancer who are treated with adjuvant chemotherapy and tamoxifen, according to research presented at SSO 2013.
Hospital readmissions within 30 days of discharge after tumor radiofrequency ablation treatments are common, according to research presented at SSO 2013.
Multivariate nomogram models predict patients' risks of progression of adenomas to high-grade dysplasia/carcinoma in situ and invasive carcinoma in main and branch-duct intraductal papillary mucinous neoplasms of the pancreas, according to research presented at SSO 2013.
Intra-arterial therapy is associated with promising locoregional control rates among patients with intrahepatic chloangiocarcinoma, according to research presented at SSO 2013.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Arrival of CAR-T Immunotherapy Raise Hopes for Treatment and Anxieties About Costs
- St John's Wort and Cancer
- Osimertinib Granted Breakthrough Therapy Designation as First-line Treatment for EGFR-positive NSCLC
- Radiation Therapy Increases 5-year Rate of Cardiac Events in Small-cell Lung Cancer
- Pazopanib: Where Does It Stand as Adjuvant Therapy in Localized RCC?
- Nivolumab Plus Chemotherapy Improves Overall Survival and Response Rate in NSCLC
- Smoking Tobacco Increases Costs and Decreases QoL in Advanced NSCLC
- Post-surgery Chemotherapy Based on BRCA1 Levels Fails To Improve Survival in NSCLC
- NSCLC: Researchers Identify Socioeconomic Factors Linked to Overall Survival
- Savolitinib Plus Gefitinib May Be Effective in EGFR-Mutant, MET-amplified NSCLC